Michelle Fraser

Michelle Fraser currently serves as the Head of Cell and Gene Therapy at Revvity since May 2023. Prior experience includes roles at PerkinElmer, Inc. as Business Unit Manager for Base Editing and General Manager for Next Generation Sequencing from August 2020 to May 2023, and Managing Director at PerkinElmer Applied Genomics from July 2018 to August 2020. Previous leadership positions include CEO and Managing Director at RHS Limited from September 2007 to July 2018, CEO at BenEphex Biotechnologies Pty Ltd, and Business Development Manager at Bio Innovation SA. Additionally, Michelle Fraser served as a member of the Science, Innovation and Commercialisation subcommittee of the SA Economic Development Board. Educational qualifications include a Graduate Diploma from the Australian Institute of Company Directors and a PhD in Molecular Biology and Science and Technology Commercialisation from the University of Adelaide.